Data Insights

ACT-777991 by Idorsia Pharmaceutical for Type 1 Diabetes (Juvenile Diabetes): Likelihood of Approval

ACT-777991 is under clinical development by Idorsia Pharmaceutical and currently in Phase I for Type 1 Diabetes (Juvenile Diabetes). According...

Likelihood of Approval and Phase Transition Success Rate Model - ACT-777991 in Type 1 Diabetes (Juvenile Diabetes)

Data Insights

Selatogrel by Idorsia Pharmaceutical for Myocardial Infarction: Likelihood of Approval

Selatogrel is under clinical development by Idorsia Pharmaceutical and currently in Phase III for Myocardial Infarction. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Selatogrel in Myocardial Infarction

Data Insights

Cenerimod by Idorsia Pharmaceutical for Systemic Lupus Erythematosus: Likelihood of Approval

Cenerimod is under clinical development by Idorsia Pharmaceutical and currently in Phase III for Systemic Lupus Erythematosus. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Cenerimod in Systemic Lupus Erythematosus

Data Insights

Daridorexant hydrochloride by Idorsia Pharmaceutical for Post-Traumatic Stress Disorder (PTSD): Likelihood of Approval

Daridorexant hydrochloride is under clinical development by Idorsia Pharmaceutical and currently in Phase II for Post-Traumatic Stress Disorder (PTSD). According...

Likelihood of Approval and Phase Transition Success Rate Model - Daridorexant Hydrochloride in Post-Traumatic Stress Disorder (PTSD)

Data Insights

ACT-10041239 by Idorsia Pharmaceutical for Multiple Sclerosis: Likelihood of Approval

ACT-10041239 is under clinical development by Idorsia Pharmaceutical and currently in Phase I for Multiple Sclerosis. According to GlobalData, Phase...

Data Insights

IDOR-1134-2831 by Idorsia Pharmaceutical for Clostridioides difficile Infections (Clostridium difficile Associated Disease): Likelihood of Approval

IDOR-1134-2831 is under clinical development by Idorsia Pharmaceutical and currently in Phase I for Clostridioides difficile Infections (Clostridium difficile Associated...

Data Insights

Daridorexant hydrochloride by Idorsia Pharmaceutical for Post-Traumatic Stress Disorder (PTSD): Likelihood of Approval

Daridorexant hydrochloride is under clinical development by Idorsia Pharmaceutical and currently in Phase II for Post-Traumatic Stress Disorder (PTSD). According...

Data Insights

Sinbaglustat by Idorsia Pharmaceutical for Tay-Sachs Disease: Likelihood of Approval

Sinbaglustat is under clinical development by Idorsia Pharmaceutical and currently in Phase I for Tay-Sachs Disease. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Sinbaglustat in Tay-Sachs Disease

Data Insights

Daridorexant hydrochloride by Idorsia Pharmaceutical for Obstructive Sleep Apnea: Likelihood of Approval

Daridorexant hydrochloride is under clinical development by Idorsia Pharmaceutical and currently in Phase I for Obstructive Sleep Apnea. According to...